In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
After finishing at $33.76 in the prior trading day, TG Therapeutics Inc (NASDAQ: TGTX) closed at $34.22, up 1.36%. In other words, the price has increased by $1.36 from its previous closing price. On the day, 1.2 million shares were traded. TGTX stock price reached its highest trading level at $34.415 during the session, while it also had its lowest trading level at $33.5.
Ratios:
Our goal is to gain a better understanding of TGTX by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.96 and its Current Ratio is at 3.86. In the meantime, Its Debt-to-Equity ratio is 0.92 whereas as Long-Term Debt/Eq ratio is at 0.91.
On October 29, 2024, TD Cowen started tracking the stock assigning a Buy rating and target price of $50.TD Cowen initiated its Buy rating on October 29, 2024, with a $50 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Sep 11 ’25 when Lonial Sagar sold 20,852 shares for $32.24 per share. The transaction valued at 672,268 led to the insider holds 94,061 shares of the business.
Lonial Sagar bought 20,852 shares of TGTX for $672,233 on Sep 11 ’25. On Jun 13 ’25, another insider, Echelard Yann, who serves as the Director of the company, sold 10,000 shares for $36.94 each. As a result, the insider received 369,400 and left with 228,816 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TGTX now has a Market Capitalization of 5429537792 and an Enterprise Value of 4995200512. As of this moment, TG’s Price-to-Earnings (P/E) ratio for their current fiscal year is 91.45, and their Forward P/E ratio for the next fiscal year is 18.40. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.62. For the stock, the TTM Price-to-Sale (P/S) ratio is 11.96 while its Price-to-Book (P/B) ratio in mrq is 19.56. Its current Enterprise Value per Revenue stands at 11.001 whereas that against EBITDA is 58.159.
Stock Price History:
The Beta on a monthly basis for TGTX is 1.97, which has changed by 0.3927554 over the last 52 weeks, in comparison to a change of 0.1443547 over the same period for the S&P500. Over the past 52 weeks, TGTX has reached a high of $46.48, while it has fallen to a 52-week low of $21.65. The 50-Day Moving Average of the stock is 8.25%, while the 200-Day Moving Average is calculated to be -1.05%.
Shares Statistics:
The stock has traded on average 2.19M shares per day over the past 3-months and 1566380 shares per day over the last 10 days, according to various share statistics. A total of 158.03M shares are outstanding, with a floating share count of 142.93M. Insiders hold about 9.92% of the company’s shares, while institutions hold 64.25% stake in the company. Shares short for TGTX as of 1759190400 were 23608291 with a Short Ratio of 10.76, compared to 1756425600 on 24510079. Therefore, it implies a Short% of Shares Outstanding of 23608291 and a Short% of Float of 19.459999.
Earnings Estimates
Its stock is currently analyzed by 6.0 different market analysts. The consensus estimate for the next quarter is $0.3, with high estimates of $0.43 and low estimates of $0.21.
Analysts are recommending an EPS of between $0.96 and $0.53 for the fiscal current year, implying an average EPS of $0.73. EPS for the following year is $1.77, with 6.0 analysts recommending between $2.49 and $1.04.
Revenue Estimates
7 analysts predict $152.07M in revenue for. The current quarter. It ranges from a high estimate of $155M to a low estimate of $150M. As of. The current estimate, TG Therapeutics Inc’s year-ago sales were $83.88MFor the next quarter, 7 analysts are estimating revenue of $173.04M. There is a high estimate of $178.39M for the next quarter, whereas the lowest estimate is $170.3M.
A total of 7 analysts have provided revenue estimates for TGTX’s current fiscal year. The highest revenue estimate was $591.84M, while the lowest revenue estimate was $582.8M, resulting in an average revenue estimate of $587.27M. In the same quarter a year ago, actual revenue was $329MBased on 8 analysts’ estimates, the company’s revenue will be $852.25M in the next fiscal year. The high estimate is $927M and the low estimate is $692.6M.
